CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.

@article{Haining2008CpGOA,
  title={CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.},
  author={W Nicholas Haining and Jeff K Davies and Holger Kanzler and Linda Drury and Thomas Brenn and John P Evans and Jill Angelosanto and Steven Rivoli and Kate E R Russell and Suzanne George and Paul Francis George Sims and Donna S Neuberg and Xiaochun Li and Jeffrey L. Kutok and Jeffrey T Morgan and Patrick Yung Chih Wen and George Demetri and Robert Lee Coffman and Lee M. Nadler},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 17},
  pages={5626-34}
}
PURPOSE CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration. Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown. EXPERIMENTAL DESIGN We conducted a phase I study of CpG-ODN (1018 ISS) given as a vaccine adjuvant with granulocyte-macrophage… CONTINUE READING